Plasma Proteomic Biomarkers for Early Diagnosis of Lung Cancer
NCT ID: NCT05742204
Last Updated: 2025-05-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
3700 participants
OBSERVATIONAL
2023-02-01
2032-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers for Diagnosis of Lung Cancer
NCT02050100
Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China
NCT01928836
Identification of a Plasma Proteomic Signature for Lung Cancer
NCT01752101
LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
NCT06778512
A Study Developing a Non-invasive Urine-based Proteomic Model for Early Lung Cancer Detection.
NCT06733311
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lung cancer group
Patients age over 18, with confirmed diagnosis of lung cancer.
Plasma protein biomarker analysis
Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients .
Control group
Non-cancer patients including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.
Plasma protein biomarker analysis
Plasma samples of control subjects were collected.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Plasma protein biomarker analysis
Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients .
Plasma protein biomarker analysis
Plasma samples of control subjects were collected.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No treatment related to pulmonary nodules/lung cancer (including surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy, etc.)
* Complete clinical and imaging data
* Chest CT/ low-dose spiral CT reports can be provided in the last 3 months
* Voluntarily sign informed consent
Exclusion Criteria
* Clinically uncontrolled active infections, such as acute pneumonia, tuberculosis, etc.
* Received any treatment related to pulmonary nodules, such as antibiotics and hormones, in the past 4 weeks
* Complicated with other tumors and serious diseases of the heart, liver, kidney, brain, blood and other systems
* Participated in other clinical trials within the last 3 months
* Combined with liver and kidney insufficiency, hypoproteinemia and other diseases affecting protein content
* You are pregnant or breastfeeding
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Weilin Wang
Role: STUDY_CHAIR
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-1109
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.